BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 29658444)

  • 1. Development of
    Robertson AKH; Ramogida CF; Schaffer P; Radchenko V
    Curr Radiopharm; 2018; 11(3):156-172. PubMed ID: 29658444
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Evolving Clinical Role of Actinium-225 and Bismuth-213 for Targeted Alpha Therapy (TAT) - Production, Radiopharmaceutical Development and Clinical Applications.
    Radchenko V; Schaffer P; Knapp FFR
    Curr Radiopharm; 2018; 11(3):154-155. PubMed ID: 30378473
    [No Abstract]   [Full Text] [Related]  

  • 3. An Overview of Targeted Alpha Therapy with
    Morgenstern A; Apostolidis C; Kratochwil C; Sathekge M; Krolicki L; Bruchertseifer F
    Curr Radiopharm; 2018; 11(3):200-208. PubMed ID: 29732998
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NorthStar Perspectives for Actinium-225 Production at Commercial Scale.
    Harvey JT
    Curr Radiopharm; 2018; 11(3):180-191. PubMed ID: 29766832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Production of Ac-225.
    Engle JW
    Curr Radiopharm; 2018; 11(3):173-179. PubMed ID: 29669509
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Jiang Z; Revskaya E; Fisher DR; Dadachova E
    Curr Radiopharm; 2018; 11(3):215-222. PubMed ID: 29683101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies.
    Jurcic JG
    Curr Radiopharm; 2018; 11(3):192-199. PubMed ID: 29793418
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Pfannkuchen N; Bausbacher N; Pektor S; Miederer M; Rosch F
    Curr Radiopharm; 2018; 11(3):223-230. PubMed ID: 29866026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiopharmaceutical Quality Control Considerations for Accelerator-Produced Actinium Therapies.
    Abou DS; Zerkel P; Robben J; McLaughlin M; Hazlehurst T; Morse D; Wadas TJ; Pandya DN; Oyama R; Gaehle G; Nickels ML; Thorek DLJ
    Cancer Biother Radiopharm; 2022 Jun; 37(5):355-363. PubMed ID: 35695807
    [No Abstract]   [Full Text] [Related]  

  • 10. Challenges and opportunities in developing Actinium-225 radiopharmaceuticals.
    Dhiman D; Vatsa R; Sood A
    Nucl Med Commun; 2022 Sep; 43(9):970-977. PubMed ID: 35950353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Actinium-225 in targeted alpha-particle therapeutic applications.
    Scheinberg DA; McDevitt MR
    Curr Radiopharm; 2011 Oct; 4(4):306-20. PubMed ID: 22202153
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Actinium-225 targeted alpha particle therapy for prostate cancer.
    Bidkar AP; Zerefa L; Yadav S; VanBrocklin HF; Flavell RR
    Theranostics; 2024; 14(7):2969-2992. PubMed ID: 38773983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bismuth-213 and actinium-225 -- generator performance and evolving therapeutic applications of two generator-derived alpha-emitting radioisotopes.
    Morgenstern A; Bruchertseifer F; Apostolidis C
    Curr Radiopharm; 2012 Jul; 5(3):221-7. PubMed ID: 22642390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Production of high-purity radium-223 from legacy actinium-beryllium neutron sources.
    Soderquist CZ; McNamara BK; Fisher DR
    Curr Radiopharm; 2012 Jul; 5(3):244-52. PubMed ID: 22697483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progress in Targeted Alpha-Particle Therapy. What We Learned about Recoils Release from In Vivo Generators.
    Kozempel J; Mokhodoeva O; Vlk M
    Molecules; 2018 Mar; 23(3):. PubMed ID: 29510568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications.
    Miederer M; Scheinberg DA; McDevitt MR
    Adv Drug Deliv Rev; 2008 Sep; 60(12):1371-82. PubMed ID: 18514364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of
    Ondrák L; Ondrák Fialová K; Sakmár M; Vlk M; Bruchertseifer F; Morgenstern A; Kozempel J
    Nucl Med Biol; 2024; 132-133():108909. PubMed ID: 38599144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of [
    Cortez A; Josefsson A; McCarty G; Shtekler AE; Rao A; Austin Z; Nedrow JR
    Nucl Med Biol; 2020; 88-89():62-72. PubMed ID: 32799049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and synthesis of 225Ac radioimmunopharmaceuticals.
    McDevitt MR; Ma D; Simon J; Frank RK; Scheinberg DA
    Appl Radiat Isot; 2002 Dec; 57(6):841-7. PubMed ID: 12406626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retention studies of recoiling daughter nuclides of 225Ac in polymer vesicles.
    Wang G; de Kruijff RM; Rol A; Thijssen L; Mendes E; Morgenstern A; Bruchertseifer F; Stuart MC; Wolterbeek HT; Denkova AG
    Appl Radiat Isot; 2014 Feb; 85():45-53. PubMed ID: 24374072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.